狄诺塞麦(Denosumab)在骨质疏松症治疗中的研究进展

骨质疏松症(osteoporosis,OP)是困扰中老年人的代谢性骨病,药物治疗骨质疏松是目前研究的重点。狄诺塞麦是一种通过抑制破骨细胞的分化、激活从而抑制骨吸收的单克隆抗体类药物,国外临床试验中已明确证实其对改善骨密度、降低相关骨折发生率的良好作用,但目前国内尚未就此在临床展开应用。本文从狄诺塞麦的药物机制、临床疗效和不良反应等方面,综述了国外近年高质量研究,探讨其在治疗骨质疏松症方面的临床应用及最新进展。狄诺塞麦对原发性骨质疏松症具有较好的治疗效果且总体不良反应温和,尽管现存在用药策略方面争议及停药后骨折风险亟待进一步研究,总体上仍具有良好的应用前景。

Research progress of denosumab in treatment of osteoporosis

Osteoporosis (OP) is a metabolic bone disease that causes relevant fractures among middle-aged and old people. Drug therapy of OP is the crucial field of current research. Denosumab is a monoclonal antibody that inhibits bone absorption by inhibiting the differentiation and activation of osteoclasts, thus restraining bone resorption. Clinical trials abroad have clearly confirmed that denosumab has good effect on improving bone mineral density and reducing the incidence of fractures, but at present no clinical application has been carried out in our country. This paper reviews high quality oversea researches from the aspects of mechanism, the clinical curative effect, and adverse reaction of denosumab in recent years, and explores its clinical application in the treatment of osteoporosis and the latest progress. Denosumab has good effect and generally mild adverse reactions in the treatment of primary osteoporosis, although controversy exists over the medication strategy. Tt is necessary to further study the risk of fracture after drug withdrawal. In general, denosumab still has good application prospects.